GPC1 regulated by miR-96-5p, rather than miR-182-5p, in inhibition of pancreatic carcinoma cell proliferation

International Journal of Molecular Sciences

Volumn 15, Issue 4, 2014, Pages 6314-6327

  Li, Chunlong ^a   Du, Xuefei ^b   Tai, Sheng ^a   Zhong, Xiangyu ^a   Wang, Zhidong ^a   Hu, Zhanliang ^a   Zhang, Lei ^a   Kang, Pengcheng ^a   Ji, Daolin ^a   Jiang, Xingming ^a   Zhou, Qingxin ^a   Wan, Ming ^a   Jiang, Guixing ^c   Cui, Yunfu ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

GPC1; Mir 182 5p; Mir 96 5p; PC

Indexed keywords

GLYPICAN 1; MICRORNA; MICRORNA 182 5P; MICRORNA 96 5P; UNCLASSIFIED DRUG; 5' UNTRANSLATED REGION; GLYPICAN; MIRN182 MICRORNA, HUMAN; MIRN96 MICRORNA, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; 5' UNTRANSLATED REGION; CARCINOMA; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; MORTALITY; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; APOPTOSIS; BASE SEQUENCE; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION; GLYPICANS; HEK293 CELLS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 84898655708     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15046314     Document Type: Article

References (22)

1. Vincent, A.; Herman, J.; Schulick, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607-620.
2. Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605-1617.
3. Feng, M.; Gao, W.; Wang, R.; Chen, W.; Man, Y.G.; Figg, W.D.; Wang, X.W.; Dimitrov, D.S.; Ho, M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 2013, 110, E1083-E1091.
4. Aikawa Aikawa, T.; Whipple, C.A.; Lopez, M.E.; Gunn, J.; Young, A.; Lander, A.D.; Korc, M. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J. Clin. Investig. 2008, 118, 89-99.
5. Duan, L.; Hu, X.Q.; Feng, D.Y.; Lei, S.Y.; Hu, G.H. GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer. Asian J. Surg./Asian Surg. Assoc. 2013, 36, 7-12.
6. Mounajjed, T.; Zhang, L.; Wu, T.T. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum. Pathol. 2013, 44, 542-550.
7. Lee, S.; Reha, J.L.; Tzeng, C.W.; Massarweh, N.N.; Chang, G.J.; Hetz, S.P.; Fleming, J.B.; Lee, J.E.; Katz, M.H. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann. Surg. Oncol. 2013, doi:10.1245/s10434-013-3130-3.
8. Whipple, C.A.; Young, A.L.; Korc, M. A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene 2012, 31, 2535-2544.
9. Jalvy-Delvaille, S.; Maurel, M.; Majo, V.; Pierre, N.; Chabas, S.; Combe, C.; Rosenbaum, J.; Sagliocco, F.; Grosset, C.F. Molecular basis of differential target regulation by miR-96 and miR-182: The Glypican-3 as a model. Nucleic Acids Res. 2012, 40, 1356-1365.
10. Moskwa, P.; Buffa, F.M.; Pan, Y.; Panchakshari, R.; Gottipati, P.; Muschel, R.J.; Beech, J.; Kulshrestha, R.; Abdelmohsen, K.; Weinstock, D.M. et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 2011, 41, 210-220.
11. Hwang, H.W.; Mendell, J.T. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 2006, 94, 776-780.
12. Lee, R.C.; Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294, 862-864.
13. Tsuchiyama, K.; Ito, H.; Taga, M.; Naganuma, S.; Oshinoya, Y.; Nagano, K.; Yokoyama, O.; Itoh, H. Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer. Prostate 2013, 73, 827-834.
14. Guttilla, I.K.; White, B.A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 2009, 284, 23204-23216.
15. Guo, Y.; Liu, H.; Zhang, H.; Shang, C.; Song, Y. MIR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. Oncol. Lett. 2012, 4, 561-565.
16. Weeraratne, S.D.; Amani, V.; Teider, N.; Pierre-Francois, J.; Winter, D.; Kye, M.J.; Sengupta, S.; Archer, T.; Remke, M.; Bai, A.H. et al. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012, 123, 539-552.
17. Tanaka, M.; Suzuki, H.I.; Shibahara, J.; Kunita, A.; Isagawa, T.; Yoshimi, A.; Kurokawa, M.; Miyazono, K.; Aburatani, H.; Ishikawa, S. et al. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene 2013, doi:10.1038/onc.2013.204.
18. Yu, S.; Lu, Z.; Liu, C.; Meng, Y.; Ma, Y.; Zhao, W.; Liu, J.; Yu, J.; Chen, J. MIRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010, 70, 6015-6025.
19. Haflidadottir, B.S.; Larne, O.; Martin, M.; Persson, M.; Edsjo, A.; Bjartell, A.; Ceder, Y. Upregulation of miR-96 Enhances Cellular Proliferation of Prostate Cancer Cells through FOXO1. PLoS One 2013, 8, e72400.
20. Xu, D.; He, X.; Chang, Y.; Xu, C.; Jiang, X.; Sun, S.; Lin, J. Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells. Oncol. Rep. 2013, 29, 653-661.
21. Zhong, X.Y.; Yu, J.H.; Zhang, W.G.; Wang, Z.D.; Dong, Q.; Tai, S.; Cui, Y.F.; Li, H. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene 2012, 493, 44-51.
22. -ΔΔCt Method. Methods 2001, 25, 402-408